Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.9500
- TODAY'S CHANGE (%)0.0100 (0.2538%)
- Bid / Lots3.9500/ 2
- Ask / Lots3.9600/ 4
- Open / Previous Close3.9400 / 3.9400
- Day Range
- 52 Week Range
- Volume167,154
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 2868 | 3.94 |
| 09:34 ET | 350 | 3.935 |
| 09:36 ET | 100 | 3.93 |
| 09:39 ET | 100 | 3.9311 |
| 09:41 ET | 2050 | 3.92 |
| 09:43 ET | 1800 | 3.92 |
| 09:45 ET | 1617 | 3.91 |
| 09:48 ET | 6188 | 3.895 |
| 09:50 ET | 800 | 3.885 |
| 09:52 ET | 2041 | 3.9 |
| 09:54 ET | 301 | 3.905 |
| 09:56 ET | 3600 | 3.96 |
| 09:57 ET | 370 | 3.94 |
| 09:59 ET | 100 | 3.9399 |
| 10:01 ET | 600 | 3.91 |
| 10:03 ET | 526 | 3.9 |
| 10:06 ET | 249 | 3.8988 |
| 10:08 ET | 650 | 3.9 |
| 10:12 ET | 2592 | 3.8805 |
| 10:14 ET | 2800 | 3.9 |
| 10:15 ET | 351 | 3.91 |
| 10:17 ET | 500 | 3.9093 |
| 10:19 ET | 100 | 3.89 |
| 10:24 ET | 1310 | 3.885 |
| 10:26 ET | 1767 | 3.88 |
| 10:28 ET | 250 | 3.885 |
| 10:30 ET | 1525 | 3.89 |
| 10:33 ET | 944 | 3.9 |
| 10:37 ET | 3692 | 3.92 |
| 10:39 ET | 400 | 3.92 |
| 10:44 ET | 500 | 3.89 |
| 10:46 ET | 830 | 3.89 |
| 10:50 ET | 225 | 3.8748 |
| 10:51 ET | 2520 | 3.8601 |
| 10:53 ET | 2298 | 3.86 |
| 10:55 ET | 423 | 3.86 |
| 10:57 ET | 836 | 3.86 |
| 11:00 ET | 582 | 3.8699 |
| 11:02 ET | 866 | 3.87 |
| 11:04 ET | 100 | 3.879 |
| 11:06 ET | 100 | 3.875 |
| 11:08 ET | 300 | 3.87 |
| 11:09 ET | 15681 | 3.85 |
| 11:11 ET | 1500 | 3.85 |
| 11:13 ET | 11655 | 3.84 |
| 11:15 ET | 357 | 3.84 |
| 11:18 ET | 1258 | 3.85 |
| 11:26 ET | 500 | 3.855 |
| 11:29 ET | 300 | 3.85 |
| 11:31 ET | 251 | 3.84 |
| 11:42 ET | 400 | 3.84 |
| 11:44 ET | 250 | 3.8317 |
| 11:45 ET | 1106 | 3.84 |
| 11:47 ET | 550 | 3.8498 |
| 11:51 ET | 582 | 3.8599 |
| 11:54 ET | 100 | 3.8591 |
| 11:56 ET | 516 | 3.86 |
| 11:58 ET | 2561 | 3.87 |
| 12:00 ET | 6462 | 3.9 |
| 12:02 ET | 6411 | 3.92 |
| 12:05 ET | 400 | 3.92 |
| 12:07 ET | 100 | 3.915 |
| 12:09 ET | 100 | 3.915 |
| 12:12 ET | 837 | 3.92 |
| 12:14 ET | 200 | 3.92 |
| 12:16 ET | 600 | 3.93 |
| 12:18 ET | 5400 | 3.925 |
| 12:20 ET | 900 | 3.9236 |
| 12:21 ET | 100 | 3.925 |
| 12:23 ET | 1671 | 3.94 |
| 12:25 ET | 7180 | 3.9597 |
| 12:27 ET | 300 | 3.95 |
| 12:32 ET | 500 | 3.9405 |
| 12:34 ET | 1000 | 3.94 |
| 12:41 ET | 1500 | 3.935 |
| 12:43 ET | 600 | 3.93 |
| 12:48 ET | 1200 | 3.93 |
| 12:50 ET | 8975 | 3.92 |
| 12:54 ET | 9259 | 3.935 |
| 12:56 ET | 1800 | 3.945 |
| 12:57 ET | 103 | 3.9443 |
| 12:59 ET | 100 | 3.95 |
| 01:01 ET | 100 | 3.95 |
| 01:03 ET | 900 | 3.95 |
| 01:06 ET | 200 | 3.96 |
| 01:10 ET | 100 | 3.96 |
| 01:12 ET | 700 | 3.965 |
| 01:14 ET | 128 | 3.9688 |
| 01:15 ET | 1000 | 3.965 |
| 01:17 ET | 200 | 3.965 |
| 01:21 ET | 1065 | 3.975 |
| 01:24 ET | 800 | 3.96 |
| 01:30 ET | 300 | 3.95 |
| 01:32 ET | 100 | 3.94 |
| 01:42 ET | 100 | 3.94 |
| 01:44 ET | 600 | 3.94 |
| 01:53 ET | 100 | 3.95 |
Yesterday
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day, from 7:00AM ET on Thursday Apr 25, 2024 by Dow Jones
7:00AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 18, 2024
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024, from 7:00AM ET on Thursday Apr 18, 2024 by Dow Jones
7:00AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 3, 2024
DJ Aldeyra's Dry Eye Disease Drug May Be On Path For FDA Approval -- Market Talk, from 2:38PM ET on Wednesday Apr 03, 2024 by Dow Jones
2:38PM ET on Wednesday Apr 03, 2024 by Dow JonesDJ Aldeyra Therapeutics Raised to Outperform From Perform by Oppenheimer, from 10:09AM ET on Wednesday Apr 03, 2024 by Dow Jones
10:09AM ET on Wednesday Apr 03, 2024 by Dow Jones
Apr 2, 2024
DJ Aldeyra Therapeutics Price Target Announced at $10.00/Share by HC Wainwright & Co., from 8:54AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:54AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 232.0M | -6.2x | --- |
Verastem Inc | 233.2M | -2.3x | --- |
Zura Bio Ltd | 230.5M | -1.0x | --- |
Conduit Pharmaceuticals Inc | 228.9M | -1,003.2x | --- |
Quantum-Si Inc | 228.2M | -2.4x | --- |
Prelude Therapeutics Inc | 221.9M | -2.0x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $232.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -6.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
